DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/l4p364/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023" report to their offering.
Global Migraine Market Value to Grow Modestly by 2023 Despite Promising New Drugs, says The authors
The global migraine treatment market value is expected to undergo a modest increase over the coming years, climbing from $2.5 billion in 2012 to $3.7 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 3.6%, according to a new report from research and consulting firm The authors.
The company's latest report* states that out of the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan), the US dominated the migraine space in 2012 with a global share of 77%. It will maintain its market-leading position by 2023, with a higher share of 84%.
The authors attributes the anticipated market expansion to the introduction of novel acute migraine therapy classes, which will address the underserved population. Among the drugs that will be launched during the forecast period are Teva and NuPathe's Zecuity, Allergan's Levadex, OptiNose's AVP-825 and SUDA's SUD-001.
Alvina To, The authors's Therapy Analyst, says: Teva and NuPathe's Zecuity, the first and only iontophoretic transdermal system for migraine, will prove popular among the population that requires or prefers an alternative route of administration over the existing formulations of acute treatments. We expect the therapy to achieve sales of approximately $180.5 million by 2023.
Key Topics Covered:
1 Table of Contents
3 Disease Overview
5 Disease Management
6 Competitive Assessment
7 Opportunity and Unmet Need
8 Pipeline Assessment
9 Current and Future Players
10 Market Outlook
- RedHill Biopharma
- CoLucid Pharmaceuticals
- Revance Therapeutics
For more information visit http://www.researchandmarkets.com/research/l4p364/pharmapoint